Sugi Predict

Sugi Predict / Compounds / SCHEMBL371576

SCHEMBL371576

SCHEMBL371576

COc1cc2c(Oc3ncc(NC(=O)CC(=O)Nc4ccc(F)cc4)cc3Cl)ccnc2cc1OCC1CCNCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 6/20 0.57
▸ MERTK Q12866 4/20 0.57
▸ MET P08581 9/20 0.53
▸ KDR P35968 10/20 0.51
▸ PDGFRA P16234 7/20 0.51
▸ FLT3 P36888 3/20 0.49
▸ RET P07949 3/20 0.49
▸ KIT P10721 3/20 0.49
▸ DDR1 Q08345 2/20 0.49
▸ EGFR P00533 2/20 0.49
▸ FGFR1 P11362 2/20 0.49
▸ FLT1 P17948 2/20 0.49
▸ FLT4 P35916 2/20 0.49
▸ AURKA O14965 1/20 0.49
▸ RIPK2 O43353 1/20 0.49
▸ ABCB11 O95342 1/20 0.49
▸ ABL1 P00519 1/20 0.49
▸ ERBB2 P04626 1/20 0.49
▸ NTRK1 P04629 1/20 0.49
▸ LCK P06239 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693574 1.00 AXL (0.57) AXLMERTKMETKDRPDGFRA
SCHEMBL372418 0.91 AXL (0.70) AXLMERTKMETKDRFLT3
SCHEMBL29693565 0.90 AXL (0.56) AXLMERTKMETKDRPDGFRA
SCHEMBL371852 0.90 AXL (0.56) AXLMERTKMETKDRPDGFRA
SCHEMBL1788925 0.89 AXL (0.57) AXLMERTKMETKDRPDGFRA
SCHEMBL410959 0.88 AXL (0.55) AXLMERTKMETKDRPDGFRA
SCHEMBL371549 0.88 AXL (0.67) AXLMERTKMETKDRPDGFRA
SCHEMBL13787495 0.88 AXL (0.54) AXLMERTKMETKDRPDGFRA
SCHEMBL374524 0.86 AXL (0.52) AXLMERTKMETKDRPDGFRA
SCHEMBL20525741 0.86 AXL (0.46) AXLMERTKMETKDRPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MERTK 17/4885MET 3/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET AXL 109/4885MERTK 17/4885MET 3/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885MERTK 23/4885MET 2/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MERTK 17/4885MET 3/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MERTK 17/4885MET 3/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET AXL 109/4885MERTK 17/4885MET 3/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 AXL 241/4885MERTK 23/4885MET 2/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885MERTK 23/4885MET 2/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET AXL 109/4885MERTK 17/4885MET 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.